PCP
CAI

Perbak Capital Partners’s Caris Life Sciences CAI Stock Holding History

Perbak Capital Partners’s Portfolio CAI Stock Details CAI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$393K Buy
22,001
+14,150
+180% +$309K 0.1% 230
2025
Q4 		$212K Sell
7,851
-2,852
-27% -$80.3K 0.06% 212
2025
Q3 		$324K Buy
+10,703
New +$341K 0.06% 266

Other funds holding CAI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
JHWEPV
J. H. Whitney Equity Partners VI New Canaan, Connecticut $326M AUM
SSP
Sixth Street Partners Dallas, Texas $711M AUM 9.3% 1-Year Est. Return
Coatue Management
Coatue Management New York $29.1B AUM 96.54% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
PC
PointState Capital New York $7.9B AUM 42.31% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Perbak Capital Partners's CAI Position: Q1 2026 in Review

Perbak Capital Partners increased its Caris Life Sciences (CAI) stake by 180% in Q1 2026, buying an estimated $309K and bringing the position to 22,001 shares worth $393K. The position accounts for 0.1% of the portfolio, ranked #230.

Perbak Capital Partners first reported a position in CAI in Q3 2025 and has held it in 3 quarters since. 202 funds tracked by Wall St. Rank hold CAI as of Q1 2026.

  • Perbak Capital Partners held 22,001 shares of Caris Life Sciences worth $393K as of Q1 2026.
  • Perbak Capital Partners bought 14,150 Caris Life Sciences shares in Q1 2026, an estimated $309K.
  • Caris Life Sciences made up 0.1% of Perbak Capital Partners's portfolio in Q1 2026, its #230 holding.
  • Perbak Capital Partners first reported a position in Caris Life Sciences in Q3 2025 and has held it in 3 quarters since.
  • 202 funds tracked by Wall St. Rank held Caris Life Sciences as of Q1 2026.

Based on Perbak Capital Partners's 13F filing for Q1 2026, filed 15 May 2026.